Food and Drug Administration (FDA)

On March 22 and 23, 2012, the U.S. Food and Drug Administration (FDA) held a public hearing to explore the idea of switching some medications to treat chronic conditions and health emergencies from prescription to over- and behind-the-counter status. Representing a group of academic health...

An analysis by UCSF faculty members from the Schools of Pharmacy and Medicine has found that the half-dozen most reputable electronic drug information resources—tools commonly used by clinicians to make prescription and patient monitoring decisions—may not provide key elements of some medications’...

In the current issue of The Archives of Internal Medicine, two faculty members of the UCSF School of Pharmacy, Department of Clinical Pharmacy issue a call for prioritization in prescription labels’ increasingly long lists of adverse drug events (ADEs).

Breast cancer patients might not be getting full advantage from a genetic screening test for the protein known as HER2 to help determine if the use of trastuzumab (marketed as Herceptin) is the best course of treatment for them. For patients whose breast cancer cells produce excessive amounts of...

William Soller, PhD, UCSF faculty member and expert on food and drug law and regulations comments on the June 30, 2009 vote of a US Food and Drug Administration (FDA) advisory committee to lower the US maximum over-the-counter dose of acetaminophen and make the current maximum single dose of the...

In light of the US Food and Drug Administration (FDA) July 31, 2006 announcement that it is proceeding to work toward making emergency contraception, known as Plan B, a non-prescription product for women ages 18 and older, two UCSF School of Pharmacy clinical faculty members answer questions about...